ProtalgoNIST (PTGX), the new psoriasis drug ICOTYDE, has been approved by the FDA… expected to generate 720 billion won in revenue. Collaboration with Johnson & Johnson is highly anticipated.

Protagonist Therapeutics (PTGX) simultaneously announced the clinical trial results of its psoriasis drug ‘ICOTYDE’, FDA approval status, and progress in its rare disease treatment pipeline, enhancing medium- to long-term growth expectations. As the differentiation and stable efficacy data of its oral therapy are confirmed, the value of its collaboration with global pharmaceutical company Johnson & Johnson is becoming increasingly prominent.

According to the 1-year follow-up results of the Phase 3 trial presented at the American Academy of Dermatology (AAD) 2026 meeting, ‘ICOTYDE’ shows a trend of increasing rates of complete skin clearance (PASI100) among patients with moderate to severe plaque psoriasis over time. Among adolescent patients, approximately 60% achieved PASI100, and 86% achieved PASI90. Notably, among patients who reached PASI90 by week 24, 92% maintained the efficacy through week 52, demonstrating its competitiveness in terms of “durability.” In terms of safety, no new safety signals were found by week 52, and the incidence of adverse effects and infections was lower compared to existing therapies.

Based on these clinical trial results, the U.S. Food and Drug Administration (FDA) has approved ICOTYDE for the treatment of adults and patients aged 12 and older weighing over 40 kg. This approval is based on data from four Phase 3 clinical trials involving a total of 2,500 participants. Commercialization will be handled by Johnson & Johnson, and Protagonist Therapeutics will receive milestone payments and royalties. This approval will immediately bring approximately $50 million (about 72 billion Korean won) in milestone payments and open up the possibility for additional payments of up to $580 million (about 835.2 billion Korean won) in the future.

Another core pipeline drug ‘rusfertide’ is also progressing smoothly. This drug is a treatment for polycythemia vera co-developed with Takeda (TAK), and the FDA has accepted its New Drug Application (NDA) and granted priority review status. Results are expected in the third quarter of this year. The Phase 3 VERIFY study and long-term follow-up data have confirmed its ability to improve blood cell concentration control, reduce the need for phlebotomy treatments, and demonstrate a high clinical response rate. In particular, the frequency of annual phlebotomies decreased from 9.2 times to 0.7 times, which is clinically significant.

On the financial side, the company is currently still in a loss position. For 2025, the annual sales are projected to be $46 million, a significant decrease from the previous year, with a net loss of $130.1 million. However, by the end of the year, its cash and cash equivalents amounted to $646 million (about 930.2 billion Korean won), indicating no significant issues with short-term liquidity.

Management has positioned 2026 as a “turning point.” They believe that with the full launch of ICOTYDE commercialization, the potential approval of rusfertide, and the restructuring options for profit-sharing structures with Takeda, there is considerable room for improvement in the profit structure. In fact, the company plans to reassess its 50:50 profit-sharing structure in the U.S. market in the second quarter of 2026.

Meanwhile, Protagonist management has been actively participating in the JPMorgan Healthcare Conference and major investment banking events, expanding their engagement with institutional investors. Industry evaluations state, “Considering the ‘consistency’ of the clinical trial data and the structure of the partnership, the likelihood of successful commercialization is gradually increasing.”

Comment: The core competitive factors in the oral psoriasis treatment market are the convenience of use and safety. As ICOTYDE gains support from long-term data, the potential for meaningful changes in a market primarily dominated by biologics is increasing.